Dopamine Hydrochloride Articles
J&J Hooks Up With Ergo For Bromocriptine
25 February 1998
Discovery's Parkinson's Patch Effective In Phase II Trial
17 February 1998
Sensus Corp On Route To Success With GHAs?
12 February 1998
Developments At Denmark's NeuroSearch
9 February 1998
Strong Growth At Elan Corp, Net Income Up 51%
9 February 1998
Allelix Expands Lilly Research Program, Ends HMR Deal
27 January 1998
New Products In 1998; A Look Ahead
6 January 1998
First Corlopam Launch Due In USA On January 1
11 December 1997
Massive Growth For Parkinson's Market
8 December 1997
NeuroSearch Sees Successful Product Year
27 November 1997
First Data For Roche's Nepicastat In CHF
25 November 1997
Novartis Licenses Iloperidone From Titan
21 November 1997
Product License News In Brief
20 November 1997
NeuroSearch To Begin Ph I With Antidepressant
30 October 1997
Avigen's AAV Vector In Parkinson's
30 October 1997
SB's ReQuip Launched In USA
30 October 1997
Pramipexole Approved By The EMEA
23 October 1997
Emerging UK Companies At Biopartnering Europe
16 October 1997
SIBIA Parkinon's Drug Well-Tolerated
2 October 1997
First COMT Inhibitor For Parkinson's Reaches Market
1 October 1997
NeuroSearch to Begin Ph I NS2330 In UK
11 September 1997
Pfizer Enters New Product Cycle With Strong Potential
7 August 1997
Zeneca's Seroquel Gains UK Approval, Its First
5 August 1997
Ergoset "Improves Metabolism" In Study
24 July 1997
Ergo Starts Weight Loss Trial With Ergoset
17 July 1997
Zeneca's Seroquel Nears Market Approval
16 July 1997
Synthelabo's Befloxatone Potential
3 July 1997
Progress With Pfizer's Ziprasidone
3 July 1997
US FDA Panel Gives Nod To Neurex' Corlopam
3 July 1997
First Approval, In The USA, For Glaxo's Zyban
26 May 1997
Long-Term Data With SB's Ropinirole
22 April 1997
Neurogen And S-P Complete Ph I Schizophrenia Trial
10 April 1997
Entacapone And Tolcapone Near Market Introduction
26 March 1997
Janssen Accrues 1 Mill Risperdal Patient Years
25 March 1997
P&U Launches Dostinex In The USA
20 March 1997
Discovery Therapeutics' Parkinson's Patch
17 February 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
Parkinson's Patch Enters Phase II
25 November 1996
Zoloft Gets OCD Indication
4 November 1996
NeuroSearch Has PD Drug Generic Name Approved
14 October 1996
R-PR Divulges R&D Pipeline Developments
23 September 1996
Hoechst Aims For Two NCEs Each Year
23 September 1996
Satisfactory Six Months At NeuroSearch
2 September 1996
Amgen Initiates GDNF Trial In Parkinson's
19 August 1996
Zeneca Files First European Seroquel Dossier
19 August 1996
Scotia Reports Advances In Schizophrenia Therapy
5 August 1996
Janssen Receives Approval For Oral Risperdal
29 July 1996
First Launch In Japan For Talipexole
22 July 1996
First Market Launch of Serdolect
15 July 1996
First Appro For SB's ReQuip Comes From The UK
15 July 1996
Ziprasidone May Have Unique Neuroleptic Activity
8 July 1996
First Appro Of Sertindole In UK; Launch Imminent
1 July 1996
Results Of Discovery's Parkinson's Disease Therapy
24 June 1996
R-PR Receives EU Approval For Rilutek
17 June 1996
Schering-Plough Chief Gives R&D Update
10 June 1996
P&U Moves To Revamp Inherited Pipeline
3 June 1996
Ropinirole Relieves Parkinson's Symptoms
8 April 1996
New NCEs Backed In Japan
8 April 1996
European Deal For Canada's Allelix?
4 March 1996
BLS' Parkinson's Imaging Agent
12 February 1996
ReVia Launched In Canada For Alcoholism
29 January 1996
B-MS's licenses NS2214 anti-Parkinson's drug
22 January 1996
P&U Files In USA For Parkinson's Drug
15 January 1996
Zeneca Pipeline Part II: Exploratory Targets
8 January 1996
Phase III Data With Lilly's Olanzapine
8 January 1996
Zeneca Reveals Typically Strong Pipeline
18 December 1995
Astra Strengthens R&D With Increased Spending
4 December 1995
Novel Drugs Will Drive Euro Anti-Parkinson's Market
27 November 1995
Neurovation antidepressant news
13 November 1995
Neurogen And Pfizer Sign Third Product Pact
13 November 1995
Pfizer Presents Fertile Pipeline
6 November 1995
Zeneca's Phase III Data Support Seroquel Efficacy
16 October 1995
SmithKline Beecham Unveils Power Pipeline
9 October 1995
Lilly Submits Olanzapine For Approval Worldwide
2 October 1995
NeuroSearch Starts Phase I NS2214 Trials
25 September 1995
European Markets For Neuroleptic drugs
7 August 1995
Bristol-Myers research operations
31 July 1995
Schering-Plough In New Psychopharma Deal
26 June 1995
Cash For Parkinson's At NeuroSearch
26 June 1995
Ergo Science Learns From Natural Metabolic Patterns
19 June 1995
Brain Injuries: Delayed Or Immediate
19 June 1995
Sandoz's Parloel and Zaditen in France
12 June 1995
Interneuron Starts Dihydrexidine Trial
29 May 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
Dopamine Hypothesis For AAMI?
22 May 1995
Synthelabo Reports On New Products
17 April 1995
Astra Collaboration For Analgesia R&D
10 April 1995
Pharmacia Pipeline Promises Future Growth
20 March 1995
Hoechst Roussel In Canadian Deal
23 January 1995
Tanadopa Launch In Japan
16 January 1995
Highlights Of SmithKline's R&D Portfolio
2 January 1995
Arolac Launch
19 December 1994
Cell-Based Therapies For Neurological Disease
5 December 1994
Cognitive Enhancers Unveiled At ASM
21 November 1994
SmithKline Beecham On Adapting To Change
10 October 1994
Phase II Results With Lilly's Olanzapine
18 July 1994
CYTOTHERAPEUTICS TO FILE 1st IND IN SUMMER?
6 June 1994
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
